35 related articles for article (PubMed ID: 38625717)
1. Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany.
Meier N; Fuchs H; Galactionova K; Hermans C; Pletscher M; Schwenkglenks M
Pharmacoecon Open; 2024 May; 8(3):373-387. PubMed ID: 38520664
[TBL] [Abstract][Full Text] [Related]
2. The cost utility and budget impact of adjuvant racecadotril for acute diarrhea in children in Thailand.
Rautenberg TA; Zerwes U
Clinicoecon Outcomes Res; 2017; 9():411-422. PubMed ID: 28761363
[TBL] [Abstract][Full Text] [Related]
3. Creating win-win-win situations with managed entry agreements? Prioritizing gene and cell therapies within the window of opportunity.
Callenbach MHE; Goettsch WG; Mantel-Teeuwisse AK; Trusheim M
Drug Discov Today; 2024 Jun; 29(7):104048. PubMed ID: 38830504
[TBL] [Abstract][Full Text] [Related]
4. Pharmacoeconomics of genotyping-based treatment decisions in patients with chronic pain.
Morlock R; Braunstein GD
Pain Rep; 2017 Sep; 2(5):e615. PubMed ID: 29392230
[TBL] [Abstract][Full Text] [Related]
5. Analysis of long-term clinical and cost impact of etranacogene dezaparvovec for the treatment of hemophilia B population in the United States.
Yan S; McDade C; Thiruvillakkat K; Rouse R; Sivamurthy K; Wilson M
J Med Econ; 2024; 27(1):758-765. PubMed ID: 38708771
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B.
Shah J; Kim H; Sivamurthy K; Monahan PE; Fries M
Curr Med Res Opin; 2023 Feb; 39(2):227-237. PubMed ID: 36285399
[TBL] [Abstract][Full Text] [Related]
7. Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B.
Von Drygalski A; Giermasz A; Castaman G; Key NS; Lattimore S; Leebeek FWG; Miesbach W; Recht M; Long A; Gut R; Sawyer EK; Pipe SW
Blood Adv; 2019 Nov; 3(21):3241-3247. PubMed ID: 31698454
[TBL] [Abstract][Full Text] [Related]
8. Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B.
Castaman G; Coppens M; Pipe SW
Expert Rev Hematol; 2023; 16(12):919-932. PubMed ID: 37882214
[TBL] [Abstract][Full Text] [Related]
9. Assessing health plan payer's budget impact of etranacogene dezaparvovec for the treatment of hemophilia B in the United States.
Wilson M; McDade C; Thiruvillakkat K; Rouse R; Sivamurthy K; Yan S
J Manag Care Spec Pharm; 2024 Apr; ():1-12. PubMed ID: 38625717
[TBL] [Abstract][Full Text] [Related]
10. Etranacogene dezaparvovec for hemophilia B gene therapy.
Thornburg CD
Ther Adv Rare Dis; 2021; 2():26330040211058896. PubMed ID: 37181105
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
